Twelve years into sprawling litigation over its blockbuster acne drug Accutane, Hoffmann-La Roche Inc. convinced a New Jersey judge on Friday that plaintiffs had “cherry-picked” scientific research to suggest that Accutane use can cause Crohn’s Disease. The decision could help Roche’s lawyers, led by Covington & Burling, put a quick end to thousands of pending lawsuits over the drug.
Superior Court Judge Nelson Johnson in New Jersey’s Atlantic County agreed to exclude testimony from the plaintiffs’ expert witnesses in the consolidated Accutane litigation, which alleges that Roche failed to provide enough warning about the acne drug’s potential connection to forms of irritable bowel disease.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
